Lessons from the Established Status Epilepticus Treatment Trial.


Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
12 2019
Historique:
received: 30 03 2019
accepted: 27 04 2019
pubmed: 28 10 2019
medline: 28 7 2020
entrez: 27 10 2019
Statut: ppublish

Résumé

Convulsive status epilepticus (SE) is a relatively common emergency condition affecting individuals of all ages. The primary goal of treatment is prompt termination of seizures. Where first-line treatment with benzodiazepine has failed to achieve this, a condition known as established SE (ESE), there is uncertainty about which agent to use next. The Established Status Epilepticus Treatment Trial (ESETT) is a 3-arm (valproate (VPA), fosphenytoin (FOS), levetiracetam (LEV)), phase III, double-blind randomized comparative effectiveness study in patients aged 2 years and above with established convulsive SE. Enrollment was completed in January 2019, and the results are expected later this year. We discuss lessons learnt during the conduct of the study in relation to the following: ethical considerations; trial design and practical implementation in emergency settings, including pediatric and adult populations; quality assurance; and outcome determination where treating emergency clinicians may lack specialist expertise. We consider that the ESETT is already informing both clinical practice and future trial design. This article is part of the Special Issue "Proceedings of the 7th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures".

Identifiants

pubmed: 31653603
pii: S1525-5050(19)30303-8
doi: 10.1016/j.yebeh.2019.04.049
pmc: PMC6944752
mid: NIHMS1544406
pii:
doi:

Substances chimiques

Anticonvulsants 0
Benzodiazepines 12794-10-4
Levetiracetam 44YRR34555
Valproic Acid 614OI1Z5WI

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

106296

Subventions

Organisme : NINDS NIH HHS
ID : U01 NS073476
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS059041
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS056975
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS099653
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS088034
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS088023
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

N Engl J Med. 2012 Feb 16;366(7):591-600
pubmed: 22335736
Seizure. 2020 Feb;75:145-152
pubmed: 31722820
Epilepsy Res. 2011 Jan;93(1):1-10
pubmed: 20947300
Epilepsia. 2017 Apr;58(4):522-530
pubmed: 28276060
J Neurol Neurosurg Psychiatry. 2006 May;77(5):611-5
pubmed: 16614020
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Epilepsia. 2013 Jan;54(1):58-65
pubmed: 22708895
Epilepsia. 1997 Aug;38(8):907-14
pubmed: 9579892
Pediatrics. 2018 Mar;141(3):
pubmed: 30352389
Epilepsia. 2013 Sep;54 Suppl 6:89-92
pubmed: 24001084
Acad Emerg Med. 2010 Jun;17(6):659-65
pubmed: 20624149
CNS Drugs. 2014 Jul;28(7):623-39
pubmed: 24806973
Epilepsia. 2015 Oct;56(10):1515-23
pubmed: 26336950
Epilepsia. 2011 Oct;52 Suppl 8:50-2
pubmed: 21967363
Epilepsy Curr. 2016 Jan-Feb;16(1):48-61
pubmed: 26900382
Epilepsia. 2010 Apr;51(4):671-5
pubmed: 19732133
Seizure. 2014 Mar;23(3):167-74
pubmed: 24433665
BMC Med Ethics. 2016 Feb 06;17:9
pubmed: 26852412
N Engl J Med. 1985 Jul 18;313(3):145-51
pubmed: 3925335
N Engl J Med. 1998 Sep 17;339(12):792-8
pubmed: 9738086
J Neurol Neurosurg Psychiatry. 1995 Jan;58(1):44-50
pubmed: 7823066
Neurocrit Care. 2012 Aug;17(1):3-23
pubmed: 22528274
Epilepsia. 2013 Mar;54(3):393-404
pubmed: 23293881
Am J Respir Crit Care Med. 2002 Nov 15;166(10):1338-44
pubmed: 12421743
J Clin Epidemiol. 2013 Aug;66(8 Suppl):S130-7
pubmed: 23849147
Epilepsia. 2014 Apr;55(4):475-82
pubmed: 24730690

Auteurs

Hannah R Cock (HR)

St George's University of London and Atkinson Morley Regional Epilepsy Network, St George's University Hospitals NHS Foundation Trust, London, UK. Electronic address: hannahrc@sgul.ac.uk.

Lisa D Coles (LD)

Department of Experimental and Clinical Pharmacology, College of Pharmacy and Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN, USA.

Jordan Elm (J)

Department of Public Health Science, Medical University of South Carolina, Charleston, SC, USA.

Robert Silbergleit (R)

Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA.

James M Chamberlain (JM)

Division of Emergency Medicine, Children's National Health System and the Department of Pediatrics and Emergency Medicine, School of Medicine and Health Sciences, George Washington University Washington, DC, USA.

James C Cloyd (JC)

Department of Experimental and Clinical Pharmacology, College of Pharmacy and Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN, USA.

Nathan Fountain (N)

Department of Neurology (Fountain, Kapur), Brain Institute, University of Virginia, Charlottesville, VA, USA.

Shlomo Shinnar (S)

Departments of Neurology, Pediatrics and Epidemiology and Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

Dan Lowenstein (D)

Department of Neurology, University of California, San Francisco, CA, USA.

Robin Conwit (R)

National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.

Thomas P Bleck (TP)

Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Jaideep Kapur (J)

Department of Neurology (Fountain, Kapur), Brain Institute, University of Virginia, Charlottesville, VA, USA; Department of Neuroscience (Kapur), Brain Institute, University of Virginia, Charlottesville, VA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH